This content is from: Portfolio A Jim Simons Market Mystery — Solved? A secretive investment fund backed by the legendary quant displays a penchant for biotech stocks. There’s a good reason for that. By Richard Teitelbaum February 07, 2023
This content is from: Culture Where the First Graduates of Yale’s Asset Management Program Landed Recipients of the one-year master’s degree now work at top hedge funds, traditional asset managers, and public pensions. By Michael Thrasher March 31, 2023
This content is from: Premium AQR Leads Multistrats in February Most funds are up by low- to mid-single-digit percentages for the year. By Stephen Taub March 08, 2023
This content is from: Premium Why Macro Investor Ken Tropin Is Cautiously Optimistic After posting his best results in several years, the founder of Graham Capital doesn’t think 2023 will be as strong for macro traders. By Stephen Taub February 22, 2023
This content is from: Premium Haidar Jupiter Takes a 5 Percent Hit Rokos, AQR, and Graham Capital led macro funds in a mixed month for the strategy. By Stephen Taub March 09, 2023
This content is from: Portfolio Here’s Why the Illiquidity Premium Is a Bad Reason to Invest in PE Investors go into private markets knowing they can’t easily sell their funds — an expectation that eliminates the compensation for tying up their money. By Julie Segal January 25, 2023
